RxDoctor Payments DataLook up a doctor →

Erin Tanner, NP

Nurse Practitioner · Alabaster, ALNPI 1588952774

Payments from drug & device makers

$140,543in general payments, 2019–2025

Across 1,037 payments — averaging $135.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$84K
  • AbbVie$19K
  • Ironwood Pharmaceuticals, Inc$15K
  • Madrigal Pharmaceuticals$12K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • plus $7K from 34 others

What the payments were for

  • Speaking & faculty fees$102,66973%
  • Travel & lodging$15,28411%
  • Food & beverage$22,42916%
  • Education$1610%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$140,543 in reported general payments places this provider in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$26,856
Medicare patients
209
Services billed
533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide113$105,604
CreonLipase/Protease/Amylase21$68,979
XifaxanRifaximin14$42,375
ZenpepLipase/Protease/Amylase14$25,414
Dexlansoprazole DrDexlansoprazole39$11,448
Mesalamine20$9,606
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates133$8,264
Budesonide DrBudesonide45$6,665
Ursodiol29$5,981
Methscopolamine Bromide45$5,591
Pantoprazole Sodium415$5,516
Colestipol Hcl78$5,390
Esomeprazole Magnesium47$4,141
Lubiprostone11$2,610
Dicyclomine Hcl113$2,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$18,967$174,583134 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$2,623$42,37514 claims
Aimmune Therapeutics, Inc.Zenpep$313$25,41414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Alabaster

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →